269 related articles for article (PubMed ID: 17229768)
21. Biweekly pegylated liposomal doxorubicin as second-line treatment in patients with relapsed ovarian cancer after failure of platinum and paclitaxel: results from a multi-center phase II study of the NOGGO.
Oskay-Oezcelik G; Koensgen D; Hindenburg HJ; Klare P; Schmalfeldt B; Lichtenegger W; Chekerov R; Al-Batran SE; Neumann U; Sehouli J;
Anticancer Res; 2008; 28(2B):1329-34. PubMed ID: 18505074
[TBL] [Abstract][Full Text] [Related]
22. Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia: a literature review of pharmaceutical and clinical aspects.
Zhu Y; Wang F; Zhao Y; Zheng X
Eur J Hosp Pharm; 2020 Jun; 28(3):124-8. PubMed ID: 32591480
[TBL] [Abstract][Full Text] [Related]
23. A comparison of overall survival with 40 and 50mg/m
Nakayama M; Kobayashi H; Takahara T; Nishimura Y; Fukushima K; Yoshizawa K
Gynecol Oncol; 2016 Nov; 143(2):246-251. PubMed ID: 27612976
[TBL] [Abstract][Full Text] [Related]
24. Reduction in skin and mucosal toxicity with pegylated liposomal doxorubicin utilizing every 2-week dosing.
Rose PG; Purpura D; Petersen L
Anticancer Drugs; 2019 Jul; 30(6):636-639. PubMed ID: 30973518
[TBL] [Abstract][Full Text] [Related]
25. Effectiveness of a nursing support program for patients with recurrent ovarian cancer receiving pegylated liposomal doxorubicin (Caelyx/Doxil).
Grenier N; Lebel V; Gill M; Mullen T; Mitchinson K; Sebborn K; Pouliot JF
Can Oncol Nurs J; 2007; 17(3):133-40. PubMed ID: 17944313
[TBL] [Abstract][Full Text] [Related]
26. Palmar-plantar erythrodysesthesia associated with chemotherapy and its treatment.
Farr KP; Safwat A
Case Rep Oncol; 2011 Apr; 4(1):229-35. PubMed ID: 21537373
[TBL] [Abstract][Full Text] [Related]
27. Symptom management: the utility of regional cooling for hand-foot syndrome induced by pegylated liposomal doxorubicin in ovarian cancer.
Bun S; Yunokawa M; Tamaki Y; Shimomura A; Shimoi T; Kodaira M; Shimizu C; Yonemori K; Fujiwara Y; Makino Y; Terakado H; Tamura K
Support Care Cancer; 2018 Jul; 26(7):2161-2166. PubMed ID: 29372396
[TBL] [Abstract][Full Text] [Related]
28. A dose escalation study of pegylated liposomal Doxorubicin (caelyx) in combination with capecitabine (xeloda) in patients with refractory solid tumors.
Maltezos E; Amarantidis K; Trichas M; Vasiliadis M; Toromanidou M; Chatzaki E; Karayiannakis A; Tsaroucha A; Romanidis K; Kakolyris S
Oncology; 2005; 69(6):463-9. PubMed ID: 16374040
[TBL] [Abstract][Full Text] [Related]
29. Treatment of recurrent platinum-resistant ovarian cancer with pegylated liposomal doxorubicin--an evaluation of the therapeutic index with special emphasis on cardiac toxicity.
Steppan I; Reimer D; Sevelda U; Ulmer H; Marth C; Zeimet AG
Chemotherapy; 2009; 55(6):391-8. PubMed ID: 19955744
[TBL] [Abstract][Full Text] [Related]
30. Kinetic targeting of pegylated liposomal doxorubicin: a new approach to reduce toxicity during chemotherapy (CARL-trial).
Eckes J; Schmah O; Siebers JW; Groh U; Zschiedrich S; Rautenberg B; Hasenburg A; Jansen M; Hug MJ; Winkler K; Pütz G
BMC Cancer; 2011 Aug; 11():337. PubMed ID: 21816044
[TBL] [Abstract][Full Text] [Related]
31. Extracorporeal Elimination of Circulating Pegylated Liposomal Doxorubicin (PLD) to Enhance the Benefit of Cytostatic Therapy in Platinum-Resistant Ovarian Cancer Patients.
Kubeček O; Bláha M; Diaz-Garcia D; Filip S
Acta Medica (Hradec Kralove); 2015; 58(1):3-8. PubMed ID: 26454800
[TBL] [Abstract][Full Text] [Related]
32. Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial.
Numico G; Castiglione F; Granetto C; Garrone O; Mariani G; Costanzo GD; Ciura PL; Gasco M; Ostellino O; Porcile G; Merlano M
Lung Cancer; 2002 Jan; 35(1):59-64. PubMed ID: 11750714
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic Apheresis, Circulating PLD, and Mucocutaneous Toxicity: Our Clinical Experience through Four Years.
Filip S; Kubeček O; Špaček J; Lánská M; Bláha M
Pharmaceutics; 2020 Sep; 12(10):. PubMed ID: 33008072
[TBL] [Abstract][Full Text] [Related]
34. Development of cutaneous squamous cell carcinoma after prolonged exposure to pegylated liposomal doxorubicin and hand-foot syndrome: a newly recognized toxicity.
Pease DF; Peterson BA; Gilles S; Hordinsky MK; Bohjanen KA; Skubitz KM
Cancer Chemother Pharmacol; 2019 Jul; 84(1):217-221. PubMed ID: 31041511
[TBL] [Abstract][Full Text] [Related]
35. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
36. Randomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancer.
Colombo N; Kutarska E; Dimopoulos M; Bae DS; Rzepka-Gorska I; Bidzinski M; Scambia G; Engelholm SA; Joly F; Weber D; El-Hashimy M; Li J; Souami F; Wing P; Engelholm S; Bamias A; Schwartz P
J Clin Oncol; 2012 Nov; 30(31):3841-7. PubMed ID: 22987083
[TBL] [Abstract][Full Text] [Related]
37. Correlation of toxicity and efficacy with pharmacokinetics (PK) of pegylated liposomal doxorubicin (PLD) (Caelyx®).
Boers-Sonderen MJ; van Herpen CM; van der Graaf WT; Desar IM; van der Logt MG; de Beer YM; Ottevanger PB; van Erp NP
Cancer Chemother Pharmacol; 2014 Sep; 74(3):457-63. PubMed ID: 24965180
[TBL] [Abstract][Full Text] [Related]
38. [Safety of PLD in the treatment of the patients with recurrent ovarian cancer--clinical experience].
Malkowska-Walczak B; Nowak-Markwitz E; Spaczyński M
Ginekol Pol; 2009 Sep; 80(9):682-6. PubMed ID: 19886242
[TBL] [Abstract][Full Text] [Related]
39. [Chinese expert consensus on management of adverse events of pegylated liposomal doxorubicin (2020 edition)].
Breast Cancer Group, Chinese Association for Clinical Oncologist (CACO)
Zhonghua Zhong Liu Za Zhi; 2020 Aug; 42(8):617-623. PubMed ID: 32867451
[TBL] [Abstract][Full Text] [Related]
40. Pegylated liposomal doxorubicin: optimizing the dosing schedule in ovarian cancer.
Rose PG
Oncologist; 2005 Mar; 10(3):205-14. PubMed ID: 15793224
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]